Developing a vaccine to protect against Shigella and ETEC infections
Official title: Advanced Development of a Combined Shigella-ETEC Vaccine
Funded at University of Maryland Baltimore · NIH-11085911 · Data updated 2026-11-12
This study is testing a new vaccine that aims to protect young children and travelers from two common causes of diarrhea, using specially modified bacteria to help the body build a strong defense against these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | June 9, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,098,552 |
| NIH project number | 5R01AI177145-03 |
| Project ID | NIH-11085911 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old, particularly those in developing countries or travelers to these regions.
✕Less likely to help
Patients who are not children or those who do not travel to areas where these pathogens are prevalent may not benefit from this research.
What this research studies
This research focuses on creating a combined vaccine that targets two major causes of diarrhea, Shigella and enterotoxigenic Escherichia coli (ETEC), which significantly affect young children and travelers. The approach involves using genetically modified strains of these bacteria to stimulate the immune system and provide protection against infections. By utilizing animal models, the researchers aim to demonstrate the effectiveness of these vaccine candidates in inducing protective immune responses. The goal is to develop a safe and effective vaccine that can be used in populations at high risk of these infections.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of severe diarrhea in children and travelers, improving health outcomes and quality of life.
How similar studies have gone: Previous research has shown promise in developing vaccines for similar pathogens, indicating that this approach has potential for success.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Barry, Eileen M. — University of Maryland Baltimore
- Study coordinator: Barry, Eileen M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.